(r) slv 319

(R)-SLV 319 is a potent and selective antagonist of cannabinoid receptor 1 (CB1) with a Ki value of 894 nM. It is the dextrorotatory counterpart of SLV 319 [1].

Ibipinabant (SLV319) is a potent, selective, and orally active cannabinoid CB1 receptor antagonist, with a K_i of 7.8 nM and over 1000-fold selectivity for CB1 compared to CB2 (K_i = 7943 nM). It is utilized in obesity and diabetes research [1] [2] [3].

(±)-Ibipinabant ((±)-SLV319) has been utilized in clinical trials for the treatment of obesity and type 2 diabetes.